Results 181 to 190 of about 214,511 (232)

Antifungal prophylaxis in neutropenic patients

International Journal of Antimicrobial Agents, 1996
Although a number of studies have been published on antifungal prophylaxis in neutropenic and bone marrow transplantation patients, there are a lot of conflicting data. Some of this may be due to a lack of consensus on the definition of fungal disease and the definition of end-points for treatment. The risk factors associated with fungal infection, the
M A Boogaerts, M A Boogaerts
exaly   +3 more sources

Targeted Antifungal Prophylaxis in Heart Transplant Recipients

Transplantation, 2013
Antifungal prophylaxis after heart transplantation is usually targeted to high-risk recipients, but the duration is normally fixed and empirical. Our purpose was to assess the efficacy of a personalized prophylactic approach based on the duration of the risk factors.In a prospective cohort, from 2003 to 2010, prophylaxis was only administered to ...
Muñoz, Patricia, Valerio, Maricela, Palomo, Jesús, GIANNELLA, MADDALENA, Yañez, Juan F., Desco, Manuel, Bouza, Emilio   +6 more
openaire   +4 more sources

Antifungal prophylaxis in neonates

Early Human Development, 2011
Fungal-related morbidity and mortality is a major concern for most neonatal intensive care units (NICUs) worldwide. Incidence rates are increasing and might be higher than reported due to the challenges associated with diagnosing fungal infections. As preterm neonates display clinical characteristics that make them prone to Candida spp infections, and ...
Manzoni P, Jacqz Aigrain E, Rizzollo S, Franco C, Stronati M, MOSTERT, Michael Martin, Farina D.   +6 more
openaire   +2 more sources

Antifungal prophylaxis in neutropenia

Current Opinion in Infectious Diseases, 1999
Despite the widespread prophylactic use of antifungal agents in neutropenic patients, invasive fungal infections continue to emerge as major causes of morbidity and mortality. With the exception of fluconazole prophylaxis in allogeneic marrow transplant recipients, no firm conclusions can be drawn due to the lack of reliable, randomized trials.
J A, Maertens, M A, Boogaerts
openaire   +2 more sources

Antifungal Prophylaxis in Immunocompromised Hosts

Annals of Pharmacotherapy, 1993
OBJECTIVE: To review the literature on the efficacy and safety of antifungal agents for prophylaxis of fungal infections in populations of immunocompromised hosts (key words: hematology-oncology, surgical, solid organ transplant, HIV infection), and to develop guidelines and recommendations regarding safe and ...
S, Reents, S D, Goodwin, V, Singh
openaire   +2 more sources

Antifungal prophylaxis in lung transplantation

International Journal of Antimicrobial Agents, 2014
Lung transplant (LTx) patients have an increased risk of developing invasive fungal infections (IFIs), particularly invasive aspergillosis. Rapid identification of the causative fungal pathogen, to allow for early administration of appropriate initial antifungal therapy, in LTx patients has been challenging due to the limited sensitivity and ...
Chin Fen, Neoh, Greg, Snell, Bronwyn, Levvey, C Orla, Morrissey, Kay, Stewart, David C M, Kong   +5 more
openaire   +2 more sources

Pharmacotherapy approaches to antifungal prophylaxis

Expert Opinion on Pharmacotherapy, 2012
Invasive fungal infection (IFI) is a serious problem due to difficulties in early diagnosis and high mortality. Different approaches are adopted for the treatment and management of IFI, including prophylactic, empiric, preemptive and directed strategies.This paper reviews the type of pharmacotherapy used for antifungal prophylaxis in infants with ...
Tzi Bun, Ng, Randy Chi Fai, Cheung, Xiu juan, Ye, Evandro Fei, Fang, Yau Sang, Chan, Wen Liang, Pan, Xiu Li, Dan, Cui Ming, Yin, Sze Kwan, Lam, Peng, Lin, Patrick Hung Kui, Ngai, Li Xin, Xia, Fang, Liu, Xiu Yun, Ye, He Xiang, Wang, Jack Ho, Wong   +15 more
openaire   +2 more sources

Antifungal Prophylaxis in Bone Marrow Transplantation

Clinical Infectious Diseases, 1990
Deep fungal infection in recipients of bone marrow transplants remains a significant cause of morbidity and mortality. Prolonged neutropenia is the major factor predisposing patients to invasive fungal disease. Candida and Aspergillus species remain the two most common pathogens.
S T, Milliken, R L, Powles
openaire   +2 more sources

Novel approaches to antifungal prophylaxis

Expert Opinion on Investigational Drugs, 2004
Antifungal prophylaxis represents a significant advance in the management of patients at risk from fungal infections in a variety of settings. Identification of patients at the highest risk and the utilisation of safe and effective drugs maximises the benefits of prophylaxis.
openaire   +2 more sources